the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose.

https://web.archive.org/web/20210823134524/fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine

FDA confirmed increase risk of heart problems from COVID 19 so called vaccine